- Company
- Pharma companies face the crisis ‘head-on'
- by Chon, Seung-Hyun Apr 3, 2023 05:49am
- The major listed pharmaceutical and bio companies were found to have significantly increased their R&D personnel over the past 3 years, during the COVID-19 pandemic. 9 out of 10 companies increased their research personnel, and the number increased by 25% during the past 3 years. According to the Financial Supervisory Service on the 31st, the
- Company
- Hugel appoints Seok-yong Cha, former CEO
- by Lee, Seok-Jun Apr 3, 2023 05:49am
- Hugel announced on the 31st that the 22nd regular general meeting of shareholders and board of directors was held and that former vice chairman of LG H&H, another non-executive director Seok-yong Cha was appointed as Hugel's new chairman and chairman of the board of directors. Chairman Cha Seok-yong served as the CEO of LG Household & Health
- Company
- AstraZeneca appoints Suyeon Kim as head of AZ Singapore
- by Eo, Yun-Ho Apr 3, 2023 05:49am
- AstraZeneca has appointed Suyeon Kim (49) from AstraZeneca Korea as General Manager of AstraZeneca Singapore. Suyeon Kim, who has been serving as the Head of the International Oncology Franchise at AstraZeneca, officially took office as General Manager on the 27th of last month. After entering Pfizer Korea as a marketing representa
- Company
- 4 out of 5 biopharmaceuticals increased exports
- by Kim, Jin-Gu Apr 3, 2023 05:49am
- Annual exports of individual pharmaceutical bio companies exceeded 2 trillion won. Last year, Samsung BioLogics recorded exports of 2.8 trillion won, up 2.3 times from the previous year, and Celltrion is also on the verge of achieving 2 trillion won. Of the 30 major listed biopharmaceutical companies, 24 showed an increase in export performance
- Company
- Bladder cancer drugs/new mechanisms appear one after another
- by Eo, Yun-Ho Mar 31, 2023 06:09am
- New treatment options for urothelial cancer are emerging one after another. Domestic commercialization of new drugs such as targeted anticancer drugs and antibody-drug conjugates (ADCs) is underway. Janssen's Balversa, which was approved at the end of last year, is suitable for patients with metastatic urinary tract disease with FGFR2 or 3 mu
- Policy
- The severity level of COVID-19 lowered from May
- by Lee, Jeong-Hwan Mar 31, 2023 06:09am
- The government announced plans to lower the severity level of COVID-19 to the alert from May and switch to a medium-level capital system. When the serious stage is lifted, the current 'temporary non-face-to-face treatment' by the current Infectious Disease Control Act is expected to end automatically. Today (29th), Prime Minister Han Deok-so
- Company
- Generic for Godex development has come to an all-stop
- by Nho, Byung Chul Mar 31, 2023 06:09am
- As pharmaceutical companies preparing to release generics for Godex announced that they would give up development, Celltrion Pharm is expected to dominate. According to the industry, about three pharmaceutical companies have been identified that are preparing generics for Godex, but drug development has been suspended due to development di
- Policy
- Cold drugs subject to PVA will be adjusted
- by Lee, Tak-Sun Mar 31, 2023 06:08am
- The government is paying close attention to the correction plan for the price volume agreement (PVA) system that will be applied to respiratory drugs such as cold medicines whose usage has increased due to COVID-19. Therefore, the schedule the authorities had set to start PVA monitoring in April after finalizing the correction plan within
- Policy
- Overseas clinical trial drugs for therapeutic purposes
- by Lee, Hye-Kyung Mar 31, 2023 06:08am
- An amendment to the Pharmaceutical Affairs Act passed the plenary session of the National Assembly on the 30th, including permitting the use of investigational drugs overseas for therapeutic purposes, establishing a basis for prompt action against online illegal activities of drugs, and strengthening education and publicity on the labeling of
- Company
- Jemperli starts reimbursement process in Korea
- by Eo, Yun-Ho Mar 31, 2023 06:08am
- Jemperli, a new cancer immunotherapy is attempting reimbursement listing in Korea. According to industry sources, GSK Korea has recently submitted an application to list its PD-1 inhibitor Jemperli (dostarlimab) for reimbursement in Korea. With the application, whether another treatment option may be released into the market remains to
